Biotech company Bioven sets sights on AIM market


  • Business
  • Saturday, 29 Aug 2015

JOHAN Indot, Halfmoon Bay Capital Ltd, the family investment vehicle of Tan Sri Wan Azmi Wan Hamzah and two other prominent Malaysians are investors in Bioven Group.

Bioven is a local biotechnology company developing a cancer drug where the research started in Cuba more than a decade ago.

Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Business , bioven group

   

Next In Business News

Ministry asks to increase electricity supply this year
Bursa Malaysia likely to trade range-bound with upside bias this week
RCE Cap to benefit from civil servant salary hike
EV production keeps demand for copper high
The Week Ahead
Westports poised to register steady earnings
Hyundai Motor to inject extra funds into Motional
EV maker Zeekr set to raise US$368mil from IPO
Press Metal begins supply to China firms
Malaysia Smelting Corp earnings set to rise

Others Also Read